Liraglutide improves peripheral perfusion and markers of angiogenesis and inflammation in people with type 2 diabetes and peripheral artery disease: An 18‐month follow‐up of a randomized clinical trial
Primary result · TcPO2Result — go to the resultEstimated treated difference 10.9 mmHg 95% CI 7.6 to 14.1 mmHgAuthors' conclusion
In people with type 2 diabetes and PAD, liraglutide increased peripheral perfusion, with amelioration of markers of angiogenesis and inflammation over an 18-month follow-up.
Study context
- Population
- People with T2D and peripheral artery disease (PAD)
- Participants
- 55 people
- Comparison
- Liraglutide vs tailored therapeutic prescriptions to manage cardiovascular risk factors (control)
- Primary endpoint
- Transcutaneous oxygen pressure (TcPO2), assessed with transcutaneous oximetry
- Follow-up
- 18 months
Methodological details18-month follow-up
- 18-month follow-up
Primary result
TcPO2
Estimated treated difference
10.9 mmHg
95% CI 7.6 to 14.1 mmHg
P < 0.001
Liraglutidevs Control
estimated treated difference 10.9 mmHg (95% CI 7.6 to 14.1 mmHg); P < 0.001
As reported in the abstract
Secondary outcomes
| Outcome | Estimated difference (mg/g Cr) (95% CI) | P value | |
|---|---|---|---|
| Urine albumin to creatinine ratio · 18 months | −103.9 (−170.8 to −37.1) | P = 0.003 | |
| −200−1000100Difference, mg/g Cr (linear scale) |
| Outcome | Estimated difference (mg/dL) (95% CI) | P value | |
|---|---|---|---|
| C-reactive protein · 18 months | −0.5 (−0.8 to −0.2) | P = 0.002 | |
| −1−0.500.5Difference, mg/dL (linear scale) |
| Outcome | Estimate | P value | |
|---|---|---|---|
| Interleukin-6 · 18 months | estimated difference −32.6 pg/mL (95% CI −54.6 to −10.5) | P = 0.004 | |
| Increase in vascular endothelial growth factor A · 18 monthsHigher increase with liraglutide | difference 70.1 pg/mL (95% CI 44.7–95.4) | P < 0.001 | |
| −100−50050100Difference, pg/mL (linear scale) |
Circulating progenitor cells and endothelial progenitor cells (CD34+, CD133+, KDR+, CD34+/KDR+, CD34+/CD133+/KDR+) · 6 and 18 months
- Significantly higher concentrations with liraglutide vs control
Original publication
Liraglutide improves peripheral perfusion and markers of angiogenesis and inflammation in people with type 2 diabetes and peripheral artery disease: An 18‐month follow‐up of a randomized clinical trial. Diabetes Obes Metab. Published 25 April 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →